Neovascular AMD is currently treated with regular intravitreal injections of anti-VEGF agents, including ranibizumab (Lucentis, Genentech, San Francisco, CA), bevacizumab (Avastin, Roche, Basel, Switzerland) and more recently aflibercept (Eylea, Regeneron, Tarrytown, New York). The gene discussed is VEGFA; the disease is age-related macular degeneration.